紫杉醇与外周血管成形术后死亡率:校正及病例匹配的多中心分析
OBJECTIVE: Paclitaxel based drug coated balloons (DCBs) and drug eluting stents (DESs) may be associated with increased mortality in patients with peripheral arterial occlusive disease (PAOD), based on a recent meta-analysis.…
要点
- 在校正相关危险因素后,紫杉醇治疗与中位24个月随访死亡率无关联。
- 间歇性跛行和慢性肢体威胁性缺血亚组中,紫杉醇均未显著增加死亡风险。
- 紫杉醇剂量及药物涂层球囊或药物洗脱支架类型与死亡率无关。
核心结论
- 校正相关危险因素后,外周动脉闭塞性疾病患者股腘动脉紫杉醇基内皮治疗与中期死亡率无关联。
主要发现
- 紫杉醇剂量及药物涂层球囊或药物洗脱支架的使用在所有亚分析中均与死亡率无关。
临床怎么用
- 对于股腘动脉病变的外周动脉闭塞性疾病患者,使用紫杉醇药物涂层球囊或药物洗脱支架时,无需因担忧中期死亡率而避免使用。
局限性
- 本研究为回顾性队列研究,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Paclitaxel based drug coated balloons (DCBs) and drug eluting stents (DESs) may be associated with increased mortality in patients with peripheral arterial occlusive disease (PAOD), based on a recent meta-analysis. This study, however, had a number of limitations, which have been discussed at great length among the vascular community. The aim of this research was to assess the association between paclitaxel based endovascular treatment (PTX) in the femoropopliteal (F-P) segment and mortality, adjusting for relevant risk factors and including patients with chronic limb threatening ischaemia (CLTI). METHODS: This was a retrospective cohort study of a prospectively maintained multicentre (three sites) database of patients with claudication or CLTI. Patients having F-P angioplasty between 1 January 2014 and 30 May 2019 with or without PTX were included. Survival was compared in Cox regression analyses adjusted for parameters of the Charlson comorbidity index. A separate nested case matched (based on each individual's Charlson index) analysis was performed to compare mortality rates between those who received PTX and those who did not. RESULTS: A total of 2 071 patients were analysed: 966 patients (46.6%) were treated with PTX (952 [46%] had CLTI and 1 119 [54%] severe claudication [Rutherford stage 3]). Over a 24 month median follow up, 456 (22.1%) patients died. Using multivariable Cox regression, PTX was not associated with mortality (HR 0.94, p = .46), even when assessed separately for those with intermittent claudication (HR 1.30, p = .15) or CLTI (HR 0.81, p = .060). In the case matched analysis (885 matched pairs of patients), PTX was not associated with mortality (HR 0.89, p = .17). Paclitaxel dose and use of a DCB or DES were not associated with mortality in any subanalysis. CONCLUSION: When relevant risk factors were taken into account, there were no associations between PTX and mid term mortality in patients with PAOD.
引用
- Saratzis A, Lea T, Yap T, et al. Paclitaxel and Mortality Following Peripheral Angioplasty: An Adjusted and Case Matched Multicentre Analysis. Eur J Vasc Endovasc Surg. 2020. PMID: 32370918. doi:10.1016/j.ejvs.2020.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。